Novel cyclic heptapeptides as potential therapeutics against methicillin-resistant Staphylococcus aureus infections
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04863-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Mohammed Sharif Shaik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Applied Science and Humanities, Vignan's Foundation for Science Technology and Research, Vadlamudi - 522213, Guntu…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Peptides, Cyclic, Anti-Bacterial Agents. Die Arbeit nennt 74 Literaturangaben.
Abstract (Originalsprache)
Novel therapeutic agents for methicillin-resistant Staphylococcus aureus (MRSA) need to be developed because of the growing antibacterial resistance against MRSA. This study aimed to design and develop novel cyclic heptapeptides as potential antibacterial agents with improved efficacy and safety profiles against MRSA. Here, we designed 100 novel cyclic heptapeptides, and it was examined computationally and validated through experimental methods. The best three cyclic heptapeptides, such as Tyr6, Gly6, and Ala6, showed the binding energy between - 10.9 and - 11.23 kcal/mol. These three cyclic heptapeptides were synthesised with 94% purity using the solid-phase peptide synthesis (SPPS) strategy, showing the 18-mm zone of inhibition against MRSA in the study of biological activities. Antibacterial evaluation against MRSA, methicillin-sensitive Staphylococcus aureus (MSSA), and vancomycin-resistant Staphylococcus aureus (VRSA) revealed that cyclic heptapeptide Ala6 shown the strongest activity (minimum inhibitory concentration (MIC), 22.1-39.5 µg/mL), comparable to moxifloxacin, followed by cyclic heptapeptide Gly6 (moderate activity) and Tyr6 (least activity). Time-kill assays showed that cyclic heptapeptide Ala6 achieved up to 89.9% colony-forming unit (CFU) reduction in MSSA at 4 × MIC within 5 h. Hemolysis testing confirmed cyclic heptapeptide Ala6's excellent biocompatibility ( 9.3% at 10 µg/mL), while moxifloxacin caused minimal hemolysis. The best peptide was further investigated through molecular dynamics (MD) simulations and density functional theory (DFT) studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Applied Science and Humanities, Vignan's Foundation for Science Technology and Research, Vadlamudi - 522213, Guntur, Andhra Pradesh, India.
- Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian and Avedisian School of Medicine, 700 Albany Street, Boston, MA, 02118, USA.
- Department of Chemistry, School of Applied Science and Humanities, Vignan's Foundation for Science Technology and Research, Vadlamudi - 522213, Guntur, Andhra Pradesh, India. drvsd_sh@vignan.ac.in.
Zitieren
APA
Shaik, M. S., Jerra, V. S., Ramachandran, B., & Venkatesan, S. (2025). Novel cyclic heptapeptides as potential therapeutics against methicillin-resistant Staphylococcus aureus infections. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04863-9
Vancouver
Shaik MS, Jerra VS, Ramachandran B, Venkatesan S. Novel cyclic heptapeptides as potential therapeutics against methicillin-resistant Staphylococcus aureus infections. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04863-9
BibTeX
@article{Shaik2025,
author = {Shaik, Mohammed Sharif and Jerra, Vidya Sagar and Ramachandran, Balajee and Venkatesan, Srinivasadesikan},
title = {Novel cyclic heptapeptides as potential therapeutics against methicillin-resistant Staphylococcus aureus infections},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04863-9}
}
EUVIMED